caption
stringlengths
0
3.92k
molecule
stringlengths
1
914
properties
listlengths
1
113
additional_data
dict
The molecule is a energy storage and is part of the thyroxine treatment class, affecting obesity, atherosclerosis, metabolic syndrome, and pancreatitis. The molecule is a membrane stabilizer that impacts both cancer and cardiovascular disease. The molecule is a nutrient, inflammatory, fat storage, energy source.
CCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)C
[ "Energy storage", "Obesity", "Thyroxine treatment", "Atherosclerosis", "Metabolic syndrome", "Pancreatitis", "Cancer", "Membrane stabilizer", "Cardiovascular disease", "nutrient", "inflammatory", "Fat storage", "Energy source" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is anti bacterial.
CNCC(O)CC1NC(=O)C(NC)Cc2cc(ccc2O)-c2ccc(O)c(c2)CC(C(=O)O)NC1=O
[ "anti bacterial" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a food additive, membrane stabilizer, surfactant, emulsifier, energy storage, and smooth. It has an effect on cervical cancer, impacting both atherosclerosis and ulcerative colitis. The molecule is a nutritional supplement, a nutrient, and a energy source, and it impacts breast cancer.
CCCc1oc(CCCCCCCCC(=O)OCC(COP(=O)(O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCc2oc(CCC)c(C)c2C)c(C)c1C
[ "food additive", "Membrane stabilizer", "Smooth", "surfactant", "Emulsifier", "Energy storage", "Atherosclerosis", "Cervical cancer", "Ulcerative colitis", "Nutritional supplement", "nutrient", "Breast cancer", "Energy source" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a renin inhibitor.
COC(=O)C1CN(C(=O)OC(C)(C)C)CC(O[Si](C)(C)C(C)(C)C)C1c1cccc(-c2ccc(F)cc2)c1
[ "renin inhibitor" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a anti parasitic.
O=C(Nc1ccc(F)c(-n2cc3cc(N4CCC4)cnc3n2)c1)c1ccco1
[ "anti parasitic" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a stabilizing mitochondrial structure and a stabilizing cytochrome oxidase that impacts tangier disease, barth syndrome, and non-alcoholic fatty liver disease. The molecule is a apoptosis, proton trap for oxidative phosphorylation, cholesterol translocation that impacts aging and diabetic heart disease.
CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC
[ "Stabilizing mitochondrial structure", "Tangier disease", "Barth syndrome", "Non-alcoholic fatty liver disease", "Stabilizing cytochrome oxidase", "Aging", "Diabetic heart disease", "Apoptosis", "Proton trap for oxidative phosphorylation", "Cholesterol translocation" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, energy storage. The molecule is a membrane stabilizer and a food additive that impacts tangier disease, barth syndrome, and non-alcoholic fatty liver disease. The molecule is a nutritional s...
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCC/C=C\CCCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC
[ "Stabilizing cytochrome oxidase", "Proton trap for oxidative phosphorylation", "Stabilizing mitochondrial structure", "Energy storage", "Tangier disease", "Barth syndrome", "Membrane stabilizer", "Non-alcoholic fatty liver disease", "food additive", "Nutritional supplement", "Smooth", "Diabeti...
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a apoptosis, a nutritional supplement, and a membrane stabilizer, and it impacts non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase, which impacts both aging and tangier disease, and is characterized as smooth. The molecule...
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC
[ "Apoptosis", "Nutritional supplement", "Membrane stabilizer", "Non-alcoholic fatty liver disease", "Proton trap for oxidative phosphorylation", "Aging", "Tangier disease", "Smooth", "Stabilizing cytochrome oxidase", "Diabetic heart disease", "Energy storage", "Cholesterol translocation", "su...
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a kinase inhibitor.
CC(=O)CCC(=O)NC(Cc1c[nH]c2ccccc12)C(=O)C(C)C
[ "kinase inhibitor" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a nutrient.
CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](N)C(=O)O)OC(=O)CCCCCCC[C@H](O)[C@@H](O)C/C=C\CCCCC
[ "nutrient" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, cholesterol translocation that impacts diabetic heart disease and tangier disease. The molecule is a stabilizing mitochondrial structure and a apoptosis that impacts barth syndrome, non-alcoholic fatty liver disease, and aging.
CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC(C)C
[ "Stabilizing cytochrome oxidase", "Proton trap for oxidative phosphorylation", "Diabetic heart disease", "Cholesterol translocation", "Tangier disease", "Barth syndrome", "Non-alcoholic fatty liver disease", "Stabilizing mitochondrial structure", "Apoptosis", "Aging" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is cancer treatment.
COC(=O)c1csc(C2Sc3ccccc3NC(=O)C2N(C(=O)Cc2cc(F)cc(F)c2)C(=O)C(C)N)c1
[ "cancer treatment" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a nutrient that affects both breast cancer and cervical cancer, and also impacts ulcerative colitis and atherosclerosis.
CCCCCCCC/C=C\CCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCCO
[ "Breast cancer", "Ulcerative colitis", "Atherosclerosis", "nutrient", "Cervical cancer" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is anti inflammatory and it impacts inflammation treatment.
NS(=O)(=O)c1ccc(-c2nn(Cc3ccccc3)c(C(=O)O)c2-c2ccc(Cl)cc2)cc1
[ "anti inflammatory", "inflammation treatment" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a membrane stabilizer and a nutrient, which impacts obesity, atherosclerosis, and pancreatitis, and is characterized as thyroxine treatment. The molecule is a energy source that impacts both cancer and metabolic syndrome. The molecule is a energy storage, a fat storage, and a inflammatory, and it impact...
CCC(C)CCCCCCCCCCCCCCCCCCCCC(=O)O[C@@H](COC(=O)CCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCC(C)C
[ "Obesity", "Atherosclerosis", "Membrane stabilizer", "Pancreatitis", "Thyroxine treatment", "nutrient", "Cancer", "Metabolic syndrome", "Energy source", "Energy storage", "Fat storage", "Cardiovascular disease", "inflammatory" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
It impacts pain treatment.
C=CCON=C(CCC(=O)OCC)c1nc2ccccc2n(C2CC3CCCC(C2)N3C2CC3CCCC(C3)C2)c1=O
[ "pain treatment" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a stabilizing cytochrome oxidase and a cholesterol translocation that impacts aging, diabetic heart disease, and tangier disease. The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, apoptosis that impacts barth syndrome and non-alcoholic fatty liver disease.
CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC(C)CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC)OC(=O)CCCCCCCCCC(C)C
[ "Stabilizing cytochrome oxidase", "Cholesterol translocation", "Aging", "Diabetic heart disease", "Tangier disease", "Stabilizing mitochondrial structure", "Barth syndrome", "Proton trap for oxidative phosphorylation", "Apoptosis", "Non-alcoholic fatty liver disease" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a cholesterol translocation and a proton trap for oxidative phosphorylation that impacts tangier disease, non-alcoholic fatty liver disease, and diabetic heart disease. The molecule is a stabilizing cytochrome oxidase, stabilizing mitochondrial structure, apoptosis that impacts aging and barth syndrome.
CCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC)OC(=O)CCCCCCCCCCCCCCC
[ "Tangier disease", "Non-alcoholic fatty liver disease", "Diabetic heart disease", "Cholesterol translocation", "Proton trap for oxidative phosphorylation", "Aging", "Stabilizing cytochrome oxidase", "Stabilizing mitochondrial structure", "Apoptosis", "Barth syndrome" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a energy source and a cholesterol translocation, impacting both non-alcoholic fatty liver disease and tangier disease. The molecule is a emulsifier, energy storage, proton trap for oxidative phosphorylation, apoptosis that impacts aging. The molecule is a surfactant, a food additive, and a nutritional s...
CC(C)CCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCC(C)C)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCC(C)C
[ "Energy source", "Non-alcoholic fatty liver disease", "Tangier disease", "Cholesterol translocation", "Emulsifier", "Energy storage", "Aging", "Proton trap for oxidative phosphorylation", "Apoptosis", "surfactant", "food additive", "Nutritional supplement", "Barth syndrome", "Smooth", "S...
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a nutrient, membrane stabilizer, emulsifier, energy source, surfactant, energy storage.
CCCCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)/C=C/CC/C=C(\C)CCCCCCCCC
[ "nutrient", "Membrane stabilizer", "Emulsifier", "Energy source", "surfactant", "Energy storage" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a cholesterol translocation, apoptosis, proton trap for oxidative phosphorylation that impacts aging and barth syndrome. The molecule is a stabilizing mitochondrial structure and a stabilizing cytochrome oxidase that impacts diabetic heart disease, tangier disease, and non-alcoholic fatty liver disease.
CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC
[ "Cholesterol translocation", "Apoptosis", "Aging", "Barth syndrome", "Proton trap for oxidative phosphorylation", "Stabilizing mitochondrial structure", "Diabetic heart disease", "Tangier disease", "Stabilizing cytochrome oxidase", "Non-alcoholic fatty liver disease" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is both a platelet aggregation inhibitor and a par4 inhibitor.
COc1cc(OCc2ccc(F)cc2)c2cc(-c3cn4nc(OC)sc4n3)oc2c1
[ "platelet aggregation inhibitor", "par4 inhibitor" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
It belongs to the anti viral agent, anti viral, and cancer treatment classes of molecules.
CCC1OC(C)C(OP(OCC2OC(C)C(C)C2C)N(CC)CC)C1C
[ "anti viral agent", "anti viral", "cancer treatment" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, apoptosis that impacts tangier disease and non-alcoholic fatty liver disease. The molecule is a stabilizing mitochondrial structure and a proton trap for oxidative phosphorylation that impacts diabetic heart disease, aging, and barth syndrome.
CCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCC(C)CC
[ "Tangier disease", "Cholesterol translocation", "Stabilizing cytochrome oxidase", "Apoptosis", "Non-alcoholic fatty liver disease", "Diabetic heart disease", "Stabilizing mitochondrial structure", "Proton trap for oxidative phosphorylation", "Aging", "Barth syndrome" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a anti bacterial and belongs to the anti microbial class of molecules.
CCCC[N+](C)(C)CCC(C)(C)N(Cl)Cl
[ "anti microbial", "anti bacterial" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is both a gsk3 inhibitor and a protein kinase inhibitor.
N#Cc1ccc(NCCNc2nc(-c3ccc(Cl)cc3Cl)nc3ccccc23)cc1
[ "gsk3 inhibitor", "protein kinase inhibitor" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a nutrient that impacts ulcerative colitis, atherosclerosis, breast cancer, and cervical cancer.
CCCCCc1oc(CCCCCCCCCCC(=O)O[C@H](COC(=O)CCC/C=C/C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]2O)COP(=O)([O-])OCC[N+](C)(C)C)c(C)c1C
[ "Ulcerative colitis", "Atherosclerosis", "nutrient", "Breast cancer", "Cervical cancer" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
It belongs to the endothelin antagonist class of molecules.
CCCOc1ccc(C2C(C(=O)O)C(c3cc(OC)c4c(c3)OCO4)CN2C(C(N)=O)c2c(CC)cccc2CC)cc1OC
[ "endothelin antagonist" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a bet inhibitor.
Cc1noc(C)c1-c1cnc2c(-c3cnn(CC(F)(F)F)c3)cn(CC3CCC(F)(F)CC3)c2c1
[ "bet inhibitor" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a apoptosis, a proton trap for oxidative phosphorylation, and a nutritional supplement, and it impacts diabetic heart disease. The molecule is a energy storage, surfactant, stabilizing mitochondrial structure, emulsifier, and smooth. The molecule is a food additive and a stabilizing cytochrome oxidase, ...
CC(C)CCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCC(C)C)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)C
[ "Apoptosis", "Diabetic heart disease", "Proton trap for oxidative phosphorylation", "Nutritional supplement", "Energy storage", "surfactant", "Stabilizing mitochondrial structure", "Smooth", "Emulsifier", "food additive", "Non-alcoholic fatty liver disease", "Tangier disease", "Stabilizing c...
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a nutrient that affects cervical cancer by impacting atherosclerosis, breast cancer, and ulcerative colitis.
CCCCC/C=C\C/C=C\C/C=C\C=C\C(=O)CCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC
[ "Cervical cancer", "Atherosclerosis", "Breast cancer", "nutrient", "Ulcerative colitis" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a tyrosine kinase inhibitor.
Cc1c(C(=O)NC2CCN(c3nc(-c4cncc(N5CCN(CCO)CC5)n4)cnc3N)CC2)c(=O)n(-c2ccccc2Cl)n1C
[ "tyrosine kinase inhibitor" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts barth syndrome, non-alcoholic fatty liver disease, and aging. The molecule is a cholesterol translocation, stabilizing mitochondrial structure, apoptosis that impacts diabetic heart disease and tangier disease.
CCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCCCC(C)C
[ "Proton trap for oxidative phosphorylation", "Stabilizing cytochrome oxidase", "Barth syndrome", "Non-alcoholic fatty liver disease", "Aging", "Cholesterol translocation", "Diabetic heart disease", "Stabilizing mitochondrial structure", "Tangier disease", "Apoptosis" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
It belongs to the electronic device class of molecules.
O=C(c1ccc(-c2ccc3c(-c4ccccc4)c4cc(-c5ccc(C(=O)c6ccccc6O)cc5)ccc4c(-c4ccccc4)c3c2)cc1)c1ccccc1O
[ "electronic device" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a nutrient.
O=C(OC(C(=O)O)C(O)C(O)C(O)C(=O)O)c1cc(O)c(O)c(O)c1
[ "nutrient" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a member of the thyroxine treatment class and affects both atherosclerosis and cardiovascular disease. The molecule is a nutrient and a fat storage, impacting both metabolic syndrome and pancreatitis.
CCCCC/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COC(=O)CCCCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCCCCCC
[ "Thyroxine treatment", "Atherosclerosis", "Cardiovascular disease", "Metabolic syndrome", "Pancreatitis", "nutrient", "Fat storage" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a pain treatment and belongs to the cannabinoid receptor modulator class of molecules, impacting inflammation treatment.
CNC(=O)C(NC(=O)c1nc(-c2cc(F)c(F)cc2F)n2c1CN(C(C)=O)CCC2)C(C)(C)C
[ "pain treatment", "inflammation treatment", "cannabinoid receptor modulator" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a cholesterol translocation and a apoptosis that impacts non-alcoholic fatty liver disease, diabetic heart disease, and aging. The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, stabilizing cytochrome oxidase that impacts tangier disease and barth syndrome.
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCC
[ "Non-alcoholic fatty liver disease", "Diabetic heart disease", "Cholesterol translocation", "Apoptosis", "Aging", "Proton trap for oxidative phosphorylation", "Tangier disease", "Stabilizing mitochondrial structure", "Barth syndrome", "Stabilizing cytochrome oxidase" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a apoptosis and a stabilizing cytochrome oxidase that impacts aging, non-alcoholic fatty liver disease, and tangier disease. The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, cholesterol translocation that impacts diabetic heart disease and barth syndrome.
CC/C=C\C/C=C\C/C=C\CCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC
[ "Aging", "Apoptosis", "Non-alcoholic fatty liver disease", "Stabilizing cytochrome oxidase", "Tangier disease", "Diabetic heart disease", "Barth syndrome", "Stabilizing mitochondrial structure", "Proton trap for oxidative phosphorylation", "Cholesterol translocation" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a membrane stabilizer, energy source, energy storage, nutrient that impacts pancreatitis and obesity. The molecule is a fat storage that impacts both cancer and atherosclerosis. The molecule is a inflammatory and belongs to the thyroxine treatment class of molecules, impacting both metabolic syndrome an...
CCCCCCCCCCCCCCCCC(=O)O[C@@H](COC(=O)CCCCCCCCCCCCCCCCC(C)CC)COC(=O)CCCCCCCCC(C)C
[ "Membrane stabilizer", "Energy source", "Pancreatitis", "Energy storage", "nutrient", "Obesity", "Cancer", "Fat storage", "Atherosclerosis", "Metabolic syndrome", "Cardiovascular disease", "Thyroxine treatment", "inflammatory" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts diabetic heart disease, non-alcoholic fatty liver disease, and barth syndrome. The molecule is a apoptosis, cholesterol translocation, stabilizing mitochondrial structure that impacts tangier disease and aging.
CCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCC(C)CC
[ "Diabetic heart disease", "Non-alcoholic fatty liver disease", "Barth syndrome", "Stabilizing cytochrome oxidase", "Proton trap for oxidative phosphorylation", "Apoptosis", "Cholesterol translocation", "Stabilizing mitochondrial structure", "Tangier disease", "Aging" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a stabilizing cytochrome oxidase, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease and diabetic heart disease. The molecule is a apoptosis and a cholesterol translocation that impacts aging, barth syndrome, and tangier disease.
CCCCCC/C=C\C=C/CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C
[ "Non-alcoholic fatty liver disease", "Stabilizing cytochrome oxidase", "Diabetic heart disease", "Stabilizing mitochondrial structure", "Proton trap for oxidative phosphorylation", "Apoptosis", "Aging", "Barth syndrome", "Cholesterol translocation", "Tangier disease" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a proton trap for oxidative phosphorylation and a cholesterol translocation that impacts diabetic heart disease, aging, and non-alcoholic fatty liver disease. The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, apoptosis that impacts tangier disease and barth syndrome.
CCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC(C)CC
[ "Proton trap for oxidative phosphorylation", "Cholesterol translocation", "Diabetic heart disease", "Aging", "Non-alcoholic fatty liver disease", "Stabilizing mitochondrial structure", "Stabilizing cytochrome oxidase", "Apoptosis", "Tangier disease", "Barth syndrome" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a anti cancer, a anti proliferative, and cancer treatment.
CNC(C)C(=O)NC1CCc2ccccc2N(Cc2cccc3cc4ccccc4cc23)C1=O.Cl
[ "anti cancer", "cancer treatment", "anti proliferative" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a anti viral.
C=CC1(COP(=O)(O)OP(=O)(O)OP(=O)(O)O)OC(N2C=CC(N)NC2=C)C(F)(F)C1O
[ "anti viral" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
It belongs to the photoresist class of molecules.
CCOC(=O)C(OCCC(F)(F)C(F)(F)S(=O)(=O)O)(OC(C)=O)C(F)(F)F
[ "photoresist" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
It impacts diabetes mellitus, insulin resistance, and neurodegenerative disease.
CC/C=C\C/C=C\C/C=C\C/C=C\C=C\C(O)CCCC(=O)N[C@@H](CO)[C@H](O)/C=C/CCCCCCCCCCCCC
[ "Diabetes mellitus", "Insulin resistance", "Neurodegenerative disease" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a food additive, a membrane stabilizer, and a energy storage, and it impacts aging. The molecule is a apoptosis, cholesterol translocation, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, and smooth. The molecule is a energy source and a nutritional supplement, impacting ...
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCCCC/C=C\CCCCCC
[ "food additive", "Membrane stabilizer", "Aging", "Energy storage", "Apoptosis", "Cholesterol translocation", "Stabilizing mitochondrial structure", "Proton trap for oxidative phosphorylation", "Smooth", "Energy source", "Nutritional supplement", "Diabetic heart disease", "Tangier disease", ...
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
It impacts metabolic syndrome, atherosclerosis, and cardiovascular disease. The molecule is a thyroxine treatment, a nutrient, and a fat storage, and it impacts pancreatitis.
CCCC/C=C\CCCCCCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\CCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC
[ "Metabolic syndrome", "Atherosclerosis", "Cardiovascular disease", "Thyroxine treatment", "nutrient", "Pancreatitis", "Fat storage" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, proton trap for oxidative phosphorylation that impacts barth syndrome and non-alcoholic fatty liver disease. The molecule is a stabilizing mitochondrial structure and a apoptosis that impacts diabetic heart disease, tangier disease, and aging.
CCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCC(C)CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCCCC
[ "Barth syndrome", "Non-alcoholic fatty liver disease", "Stabilizing cytochrome oxidase", "Cholesterol translocation", "Proton trap for oxidative phosphorylation", "Diabetic heart disease", "Tangier disease", "Stabilizing mitochondrial structure", "Apoptosis", "Aging" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a cholesterol translocation that impacts tangier disease, diabetic heart disease, aging, and barth syndrome. The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, apoptosis, proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease.
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC
[ "Tangier disease", "Diabetic heart disease", "Aging", "Cholesterol translocation", "Barth syndrome", "Non-alcoholic fatty liver disease", "Stabilizing mitochondrial structure", "Stabilizing cytochrome oxidase", "Apoptosis", "Proton trap for oxidative phosphorylation" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, apoptosis that impacts aging and diabetic heart disease. The molecule is a cholesterol translocation and a stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease, tangier disease, and barth syndrome.
CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCC(C)C
[ "Aging", "Proton trap for oxidative phosphorylation", "Diabetic heart disease", "Stabilizing mitochondrial structure", "Apoptosis", "Non-alcoholic fatty liver disease", "Tangier disease", "Cholesterol translocation", "Barth syndrome", "Stabilizing cytochrome oxidase" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is anti viral.
CC(C)(C)OC(=O)NC1CC=CC(O)C1NC(=O)OC(C)(C)C
[ "anti viral" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
It belongs to the photosensitive class of molecules.
C[Si](C)(CCCc1ccccc1O)O[Si](CCCc1ccccc1O)(c1ccccc1)c1ccccc1
[ "photosensitive" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a muscarinic receptor antagonist.
C=CC[N+]1(C)CCN(Cc2cccc(C(=O)NCc3ccc(F)c(-c4cccc(CN5CCNC(C)C5)c4)c3)c2)CC1.O=C(O)C(F)(F)F.O=C([O-])C(F)(F)F
[ "muscarinic receptor antagonist" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a cholesterol translocation, a emulsifier, and a food additive, and it impacts tangier disease. The molecule is a membrane stabilizer, energy source, apoptosis, stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease. The molecule is a nutritional supplement and a surfactant, it im...
CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC
[ "Cholesterol translocation", "Emulsifier", "Tangier disease", "food additive", "Membrane stabilizer", "Energy source", "Non-alcoholic fatty liver disease", "Apoptosis", "Stabilizing cytochrome oxidase", "Smooth", "Nutritional supplement", "surfactant", "Barth syndrome", "Diabetic heart dis...
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a nutrient that impacts cervical cancer, atherosclerosis, breast cancer, and ulcerative colitis.
CCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCC(=O)C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]1O
[ "Cervical cancer", "Atherosclerosis", "Breast cancer", "Ulcerative colitis", "nutrient" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
It belongs to the anti biotic class of molecules.
O=C(CCNC(=O)c1ccc([N+](=O)[O-])cc1)Nc1ccc(C(=O)O)cc1
[ "anti biotic" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a proton trap for oxidative phosphorylation and a cholesterol translocation that impacts diabetic heart disease, tangier disease, and non-alcoholic fatty liver disease. The molecule is a apoptosis, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts barth syndrome and aging.
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC
[ "Proton trap for oxidative phosphorylation", "Diabetic heart disease", "Tangier disease", "Non-alcoholic fatty liver disease", "Cholesterol translocation", "Apoptosis", "Stabilizing cytochrome oxidase", "Barth syndrome", "Stabilizing mitochondrial structure", "Aging" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a stabilizing mitochondrial structure and a apoptosis that impacts aging, barth syndrome, and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation that impacts diabetic heart disease and tangier disease.
CC/C=C\C/C=C\C/C=C\CCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCCCCCCCCCC
[ "Aging", "Stabilizing mitochondrial structure", "Barth syndrome", "Apoptosis", "Non-alcoholic fatty liver disease", "Cholesterol translocation", "Diabetic heart disease", "Stabilizing cytochrome oxidase", "Tangier disease", "Proton trap for oxidative phosphorylation" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a nutrient.
CCC=S=O
[ "nutrient" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, apoptosis that impacts tangier disease and diabetic heart disease. The molecule is a stabilizing mitochondrial structure and a cholesterol translocation that impacts non-alcoholic fatty liver disease, aging, and barth syndrome.
CC/C=C\C/C=C\C/C=C\CCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCC
[ "Tangier disease", "Proton trap for oxidative phosphorylation", "Diabetic heart disease", "Stabilizing cytochrome oxidase", "Apoptosis", "Stabilizing mitochondrial structure", "Cholesterol translocation", "Non-alcoholic fatty liver disease", "Aging", "Barth syndrome" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a cholesterol translocation and a apoptosis that impacts aging, diabetic heart disease, and barth syndrome. The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease and tangier disease.
CCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)CC
[ "Aging", "Diabetic heart disease", "Cholesterol translocation", "Barth syndrome", "Apoptosis", "Stabilizing mitochondrial structure", "Non-alcoholic fatty liver disease", "Tangier disease", "Proton trap for oxidative phosphorylation", "Stabilizing cytochrome oxidase" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
It impacts thyroxine treatment, atherosclerosis, and metabolic syndrome. The molecule is a nutrient and a fat storage, impacting both pancreatitis and cardiovascular disease.
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@@H](COCCCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCCCCCC
[ "Thyroxine treatment", "Atherosclerosis", "Metabolic syndrome", "nutrient", "Pancreatitis", "Cardiovascular disease", "Fat storage" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a energy storage that impacts barth syndrome, aging, and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation, surfactant, membrane stabilizer, emulsifier that impacts diabetic heart disease. The molecule is a energy source, food additive, proton trap for oxidative phosphorylat...
CC(C)CCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)C
[ "Energy storage", "Barth syndrome", "Aging", "Non-alcoholic fatty liver disease", "Cholesterol translocation", "surfactant", "Diabetic heart disease", "Membrane stabilizer", "Emulsifier", "Energy source", "food additive", "Proton trap for oxidative phosphorylation", "Nutritional supplement",...
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
It impacts atherosclerosis, cardiovascular disease, and metabolic syndrome. The molecule is a nutrient and fat storage, belonging to the thyroxine treatment class of molecules, and impacts pancreatitis.
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC)COC(=O)CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC
[ "Atherosclerosis", "Cardiovascular disease", "Metabolic syndrome", "nutrient", "Fat storage", "Pancreatitis", "Thyroxine treatment" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a membrane stabilizer, a apoptosis, a proton trap for oxidative phosphorylation, and smooth. The molecule is a nutritional supplement, surfactant, stabilizing mitochondrial structure, energy storage, energy source. The molecule is a cholesterol translocation that impacts diabetic heart disease, tangier ...
CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC
[ "Smooth", "Membrane stabilizer", "Apoptosis", "Proton trap for oxidative phosphorylation", "Nutritional supplement", "surfactant", "Stabilizing mitochondrial structure", "Energy storage", "Energy source", "Diabetic heart disease", "Cholesterol translocation", "Tangier disease", "Aging", "N...
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
It has an effect on colorectal cancer, and impacts seizure, breast cancer, and cardiovascular disease. It has an effect on stomach cancer, and impacts diabetes mellitus, alzheimer's disease, and parkinson's disease.
CC/C=C\CCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)O[C@H]1C(O)C(O)C(O)[C@@H](OP(=O)(O)O)C1O)OC(=O)CCCCCCCC(=O)/C=C/C=C\CCCCC
[ "Colorectal cancer", "Seizure", "Breast cancer", "Cardiovascular disease", "Stomach cancer", "Diabetes mellitus", "Alzheimer's Disease", "Parkinson's disease" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a nutrient.
COc1cc(-c2cc(=O)c3c(O)cc(OC4OCC(O)C(O)C4O)cc3o2)cc(OC)c1O
[ "nutrient" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is smoky, apple.rose, apple, and rose. The molecule is a surfactant, a membrane stabilizer, a emulsifier, and honey. The molecule is a nutrient, energy source, energy storage, anti spasmodic. The molecule is a anti edemic and belongs to the anti inflammatory class of molecules; it is sweet and tobacco.
CC(=O)/C=C/C1=C(C)CCCC1(C)C
[ "smoky", "apple.rose", "apple", "rose", "surfactant", "Membrane stabilizer", "honey", "Emulsifier", "nutrient", "Energy source", "Energy storage", "anti spasmodic", "anti inflammatory", "sweet", "anti edemic", "tobacco" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a apoptosis and a stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease, diabetic heart disease, and tangier disease. The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase that impacts aging and barth syndrome.
CCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC(C)C
[ "Non-alcoholic fatty liver disease", "Apoptosis", "Diabetic heart disease", "Tangier disease", "Stabilizing mitochondrial structure", "Cholesterol translocation", "Proton trap for oxidative phosphorylation", "Aging", "Barth syndrome", "Stabilizing cytochrome oxidase" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a membrane stabilizer, surfactant, energy storage, energy source, signalling molecule, emulsifier.
CCC(C)C(=O)OC
[ "Membrane stabilizer", "surfactant", "Energy storage", "Energy source", "signalling molecule", "Emulsifier" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
It impacts cardiovascular disease, breast cancer, colorectal cancer, and parkinson's disease. It has an effect on stomach cancer, and impacts seizure, alzheimer's disease, and diabetes mellitus.
CC/C=C\C/C=C\C/C=C\C/C=C\CCCCCCC(=O)O[C@H](COC(=O)CC/C=C\C/C=C\C/C=C\C=C\C(O)C/C=C\C/C=C\CC)COP(=O)(O)O[C@H]1C(O)C(O)C(O)[C@@H](OP(=O)(O)O)C1O
[ "Cardiovascular disease", "Breast cancer", "Colorectal cancer", "Parkinson's disease", "Seizure", "Alzheimer's Disease", "Stomach cancer", "Diabetes mellitus" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a proton trap for oxidative phosphorylation and a cholesterol translocation that impacts tangier disease, barth syndrome, and aging. The molecule is a apoptosis, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease and diabetic heart disease.
CCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)CC
[ "Tangier disease", "Barth syndrome", "Proton trap for oxidative phosphorylation", "Cholesterol translocation", "Aging", "Non-alcoholic fatty liver disease", "Diabetic heart disease", "Apoptosis", "Stabilizing cytochrome oxidase", "Stabilizing mitochondrial structure" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a anti depressant.
Cn1ncc(C#Cc2cccc(S(N)(=O)=O)c2)c1-c1ccc(OCC(F)(F)F)cc1
[ "anti depressant" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a infectious disease treatment that impacts cancer treatment.
CC(=O)Nc1ccc(C(=O)NCCCN(C)C)cc1[N+](=O)[O-]
[ "cancer treatment", "infectious disease treatment" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a stabilizing mitochondrial structure, apoptosis, stabilizing cytochrome oxidase that impacts barth syndrome and tangier disease. The molecule is a cholesterol translocation and a proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease, aging, and diabetic heart disease.
CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC
[ "Stabilizing mitochondrial structure", "Barth syndrome", "Apoptosis", "Tangier disease", "Stabilizing cytochrome oxidase", "Non-alcoholic fatty liver disease", "Aging", "Diabetic heart disease", "Cholesterol translocation", "Proton trap for oxidative phosphorylation" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a nutrient.
CCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCC/C=C\C[C@H]1[C@@H](O)CC(O)O[C@@H]1/C=C/[C@@H](O)CCCCC)COP(=O)(O)OC[C@H](N)C(=O)O
[ "nutrient" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
It belongs to the treatment of disorder class of molecules.
COc1cnc(COc2ccc3c(N)n[nH]c3c2)cn1
[ "treatment of disorder" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a syk inhibitor and belongs to the cancer treatment class of molecules.
Nc1cnc(C2(Br)CC2Cl)cc1N
[ "syk inhibitor", "cancer treatment" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease. The molecule is a apoptosis that impacts tangier disease, aging, barth syndrome, and diabetic heart disease.
CC/C=C\C/C=C\C/C=C\CCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC
[ "Cholesterol translocation", "Non-alcoholic fatty liver disease", "Stabilizing cytochrome oxidase", "Proton trap for oxidative phosphorylation", "Stabilizing mitochondrial structure", "Tangier disease", "Aging", "Apoptosis", "Barth syndrome", "Diabetic heart disease" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a proton trap for oxidative phosphorylation, apoptosis, stabilizing mitochondrial structure, cholesterol translocation that impacts barth syndrome. The molecule is a stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease, aging, tangier disease, and diabetic heart disease.
CCCCCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCCCCC
[ "Proton trap for oxidative phosphorylation", "Apoptosis", "Stabilizing mitochondrial structure", "Barth syndrome", "Cholesterol translocation", "Non-alcoholic fatty liver disease", "Aging", "Tangier disease", "Diabetic heart disease", "Stabilizing cytochrome oxidase" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
It belongs to both the pain treatment and inflammation treatment classes of molecules.
Cc1ccc(-c2ccc(N=O)cc2C(=O)C2CCC2)nc1
[ "pain treatment", "inflammation treatment" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a anti hypertensive and belongs to the vasopressin antagonist class of molecules.
Cc1ccc2c(c1)NC(=O)CCN2C(=O)c1ccc([N+](=O)[O-])c(C)c1
[ "anti hypertensive", "vasopressin antagonist" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a hcv inhibitor and ns5a inhibitor, belonging to the anti viral class of molecules, and is anti viral compound.
CC(=O)CC1CC(C)=NO1
[ "hcv inhibitor", "anti viral compound", "ns5a inhibitor", "anti viral" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, apoptosis, stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease. The molecule is a cholesterol translocation that impacts tangier disease, diabetic heart disease, barth syndrome, and aging.
CCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCC(C)C
[ "Stabilizing mitochondrial structure", "Non-alcoholic fatty liver disease", "Proton trap for oxidative phosphorylation", "Apoptosis", "Stabilizing cytochrome oxidase", "Tangier disease", "Diabetic heart disease", "Barth syndrome", "Cholesterol translocation", "Aging" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a apoptosis and a proton trap for oxidative phosphorylation that impacts aging, barth syndrome, and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation, stabilizing mitochondrial structure, stabilizing cytochrome oxidase that impacts tangier disease and diabetic heart disease.
CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCC
[ "Apoptosis", "Proton trap for oxidative phosphorylation", "Aging", "Barth syndrome", "Non-alcoholic fatty liver disease", "Tangier disease", "Cholesterol translocation", "Stabilizing mitochondrial structure", "Diabetic heart disease", "Stabilizing cytochrome oxidase" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a cholesterol translocation and a apoptosis that impacts aging, tangier disease, and diabetic heart disease. The molecule is a stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease and barth syndrome.
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCCCCCCCC
[ "Cholesterol translocation", "Apoptosis", "Aging", "Tangier disease", "Diabetic heart disease", "Stabilizing cytochrome oxidase", "Proton trap for oxidative phosphorylation", "Non-alcoholic fatty liver disease", "Stabilizing mitochondrial structure", "Barth syndrome" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a nutrient that impacts parkinson's disease, non-alcoholic fatty liver disease, diabetes mellitus type 2, and alzheimer's disease.
CCCCCCCC/C=C\CCCCCCCCCC(=O)O[C@H](COC(=O)CCC/C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]1O)COP(=O)(O)OCCN
[ "Parkinson's disease", "Non-alcoholic fatty liver disease", "Diabetes mellitus type 2", "nutrient", "Alzheimer's Disease" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
It influences both colorectal cancer and breast cancer, as well as affecting alzheimer's disease and stomach cancer. It impacts cardiovascular disease, parkinson's disease, diabetes mellitus, and seizure.
CC/C=C\C[C@@H](O)/C=C/C=C\C=C\[C@@H](O)C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1O)OC(=O)CCCCCCC/C=C\CCCCCC
[ "Alzheimer's Disease", "Stomach cancer", "Colorectal cancer", "Breast cancer", "Cardiovascular disease", "Parkinson's disease", "Diabetes mellitus", "Seizure" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a energy source and a stabilizing cytochrome oxidase, impacting both tangier disease and aging. The molecule is a surfactant, food additive, stabilizing mitochondrial structure that impacts diabetic heart disease and barth syndrome. The molecule is a membrane stabilizer, a energy storage, a cholesterol ...
CCC(C)CCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)CC
[ "Tangier disease", "Aging", "Energy source", "Stabilizing cytochrome oxidase", "Diabetic heart disease", "surfactant", "food additive", "Stabilizing mitochondrial structure", "Barth syndrome", "Membrane stabilizer", "Energy storage", "Smooth", "Cholesterol translocation", "Nutritional supp...
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a anti inflammatory and belongs to the ccr1 antagonist class of molecules.
COc1cc(N2CCN(C(C=O)n3ncc4c(OC)ncnc43)CC2)ccc1Cl
[ "anti inflammatory", "ccr1 antagonist" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts aging, barth syndrome, and tangier disease. The molecule is a cholesterol translocation, apoptosis, stabilizing mitochondrial structure that impacts diabetic heart disease and non-alcoholic fatty liver disease.
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCC/C=C\CCCCCC
[ "Proton trap for oxidative phosphorylation", "Stabilizing cytochrome oxidase", "Aging", "Barth syndrome", "Tangier disease", "Diabetic heart disease", "Cholesterol translocation", "Apoptosis", "Stabilizing mitochondrial structure", "Non-alcoholic fatty liver disease" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is androgen receptor modulator and it impacts treatment of disorder.
CCC(O)(CS(=O)(=O)CC(F)(F)F)c1cc2cc([N+](=O)[O-])c(C)cc2[nH]1
[ "treatment of disorder", "androgen receptor modulator" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a apoptosis, cholesterol translocation, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease. The molecule is a stabilizing mitochondrial structure that impacts tangier disease, diabetic heart disease, barth syndrome, and aging.
CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC
[ "Apoptosis", "Cholesterol translocation", "Non-alcoholic fatty liver disease", "Stabilizing cytochrome oxidase", "Proton trap for oxidative phosphorylation", "Tangier disease", "Diabetic heart disease", "Stabilizing mitochondrial structure", "Barth syndrome", "Aging" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a stabilizing cytochrome oxidase, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation that impacts diabetic heart disease and tangier disease. The molecule is a apoptosis and a cholesterol translocation that impacts aging, non-alcoholic fatty liver disease, and barth syndrome.
CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\C=C/CCCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\C=C/CCCCCC
[ "Stabilizing cytochrome oxidase", "Stabilizing mitochondrial structure", "Diabetic heart disease", "Proton trap for oxidative phosphorylation", "Tangier disease", "Aging", "Apoptosis", "Non-alcoholic fatty liver disease", "Barth syndrome", "Cholesterol translocation" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a stabilizing mitochondrial structure, cholesterol translocation, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase that impacts barth syndrome. The molecule is a apoptosis that impacts non-alcoholic fatty liver disease, aging, diabetic heart disease, and tangier disease.
CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)C
[ "Stabilizing mitochondrial structure", "Cholesterol translocation", "Proton trap for oxidative phosphorylation", "Stabilizing cytochrome oxidase", "Barth syndrome", "Non-alcoholic fatty liver disease", "Apoptosis", "Aging", "Diabetic heart disease", "Tangier disease" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a proton trap for oxidative phosphorylation and a stabilizing mitochondrial structure that impacts diabetic heart disease, non-alcoholic fatty liver disease, and aging. The molecule is a apoptosis, cholesterol translocation, stabilizing cytochrome oxidase that impacts tangier disease and barth syndrome.
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCC
[ "Diabetic heart disease", "Proton trap for oxidative phosphorylation", "Non-alcoholic fatty liver disease", "Aging", "Stabilizing mitochondrial structure", "Tangier disease", "Apoptosis", "Cholesterol translocation", "Stabilizing cytochrome oxidase", "Barth syndrome" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a stabilizing mitochondrial structure and a proton trap for oxidative phosphorylation that impacts diabetic heart disease, aging, and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, apoptosis that impacts tangier disease and barth syndrome.
CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC
[ "Diabetic heart disease", "Stabilizing mitochondrial structure", "Aging", "Non-alcoholic fatty liver disease", "Proton trap for oxidative phosphorylation", "Cholesterol translocation", "Tangier disease", "Barth syndrome", "Stabilizing cytochrome oxidase", "Apoptosis" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }
The molecule is a fat storage and a nutrient that impacts atherosclerosis, pancreatitis, cardiovascular disease, and cancer. The molecule is a energy storage and membrane stabilizer, and it impacts obesity. The molecule is a thyroxine treatment, a energy source, and a inflammatory, and it impacts metabolic syndrome.
CCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCC(C)CC
[ "Atherosclerosis", "Fat storage", "nutrient", "Pancreatitis", "Cardiovascular disease", "Cancer", "Obesity", "Energy storage", "Membrane stabilizer", "Thyroxine treatment", "Energy source", "Metabolic syndrome", "inflammatory" ]
{ "Actives": null, "Approval Date": null, "Brand Name": null, "Indication": null, "PubChem CIDs": null }